Search

Search Constraints

You searched for: Author/Creator Perna, Carla

Search Results

1. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Issue 10323 (29th January 2022)

2. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476). Issue 3 (16th May 2022)

3. Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial. Issue 4 (25th July 2022)

4. Hemi‐ablative low‐dose‐rate prostate brachytherapy for unilateral localised prostate cancer. (23rd December 2019)

5. Long‐term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low‐dose‐rate brachytherapy for localised prostate cancer. (2nd August 2017)

6. Long‐term survival after low‐dose‐rate brachytherapy for prostate cancer: the Royal Surrey experience. (22nd September 2021)

10. Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. Issue 8 (10th March 2022)